Singapore markets closed
Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,059.08 +48.48 (+0.97%) Dow
38,449.39 +209.41 (+0.55%) Nasdaq
15,648.48 +197.18 (+1.28%) Bitcoin USD
66,769.70 +853.90 (+1.30%) CMC Crypto 200
1,436.61 +21.85 (+1.54%)
Atea Pharmaceuticals, Inc. (AVIR)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 11:06AM EDT. Market open.
| Previous close | 3.6700 |
| Open | 3.6800 |
| Bid | 3.7300 x 100 |
| Ask | 3.8000 x 200 |
| Day's range | 3.6800 - 3.7600 |
| 52-week range | 2.7650 - 5.1900 |
| Volume | |
| Avg. volume | 406,006 |
| Market cap | 316.458M |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript February 28, 2024 Atea Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter 2023 Financial Results and Business Update […]
- GuruFocus.com
Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results
Highlights Clinical Progress and Financial Position
- Zacks
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.
© 2024 Yahoo. All rights reserved.